# The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy

> **NCT06746194** · — · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06746194
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06746194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06746194, "The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06746194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*